irinotecan liposome + oxaliplatin + fluorouracil + leucovorin

This combination chemotherapy regimen consists of a specific liposomal nanoparticle formulation of irinotecan (referred to as Irinotecan Liposome Injection II), oxaliplatin, fluorouracil (5-FU), and leucovorin. Primarily investigated in China, notably by Ruijin Hospital, this regimen is modeled after the FOLFIRINOX framework but utilizes a novel liposomal irinotecan delivery system. In clinical trials for pancreatic cancer with liver metastasis, the regimen is often administered via hepatic arterial infusion chemotherapy (HAIC), where oxaliplatin and the irinotecan liposome are delivered intra-arterially to target hepatic lesions directly, followed by systemic or intra-arterial administration of 5-FU and leucovorin. The mechanism of action involves the inhibition of DNA topoisomerase I by irinotecan, DNA cross-linking by oxaliplatin, and the inhibition of thymidylate synthase by fluorouracil (potentiated by leucovorin), collectively disrupting DNA replication and inducing apoptosis in tumor cells.

Other names

HAIC-FOLFIRINOXHAIC-nal-IRI+FOLFOXIrinotecan Liposome II + Oxaliplatin + 5-FU + LV